Physician profile
Robert Alan Highland
NPI 1831145036
$1,611.13
in general payments reported to CMS, 2019-2025
28 companies · $99.75 in 2025
The $99.75 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $55.60 · 2021: $97.17 · 2022: $269 · 2023: $471 · 2024: $400 · 2025: $99.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $241.18 | 2023-2025 | |
| Astellas Pharma US INC | $234.53 | 2023-2024 | Veozah, Myrbetriq |
| Roche Diagnostics Corporation | $141.97 | 2019-2021 | |
| Aspira Women'S Health INC | $127.31 | 2022 | |
| Abbvie INC. | $116.91 | 2019-2023 | |
| Masimo Corporation | $104.85 | 2020-2021 | |
| Exeltis, USA INC. | $100.97 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $66.63 | 2024 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Evofem Biosciences, INC. | $56.57 | 2022-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $44.56 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $41.51 | 2019-2024 | |
| Novo Nordisk INC | $40.82 | 2023-2024 | Wegovy |
| Shield Therapeutics INC | $31.28 | 2023-2024 | Accrufer |
| Avion Pharmaceuticals | $25.58 | 2019-2020 | |
| Coopersurgical, INC. | $25.05 | 2019-2023 | Paragard T 380a |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.73 | 2024 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $21.73 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $18.77 | 2022 | |
| Seqirus USA INC | $18.76 | 2024 | Flucelvax, Fluad |
| Daiichi Sankyo INC. | $17.83 | 2022 | |
| Boston Scientific Corporation | $17.81 | 2023 | Sq-Rx Pulse Generator |
| Otsuka America Pharmaceutical, INC. | $17.70 | 2022 | |
| Therapeuticsmd, INC. | $17.45 | 2022 | |
| Organon LLC | $17.21 | 2024 | |
| Pfizer INC. | $14.06 | 2023 | |
| Ethicon US, LLC | $13.85 | 2022 | |
| Lupin INC. | $13.51 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Highland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.